Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2255-2265

  Ekshyyan, Oleksandr ^a,b   Rong, Youhua ^a,b   Rong, Xiaohua ^a,b   Pattani, Kavita M ^a   Abreo, Fleurette ^a   Caldito, Gloria ^b   Chang, John Kai Siung ^b   Ampil, Federico ^b   Glass, Jonathan ^b   Nathan, Cherie Ann O ^a,b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; TEMSIROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; MICE; MICE, INBRED STRAINS; PROTEIN KINASES; RADIATION-SENSITIZING AGENTS; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68849099331     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1184     Document Type: Article

References (40)

1. Canto M, Devesa S. Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. Oral Oncol 2002;38:610-7.
2. Jesse R, Sugarbaker E. Squamous cell carcinoma of the oropharynx: why we fail. Am J Surg 1976;132:435-8.
3. Howell G, Grandis J. Molecular mediators of metastasis in head and neck squamous cell carcinoma. Neck 2005;27:710-7.
4. Cooper J, Pajak T, Forastiere A, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
5. Ahmed K, Samant S, Vieira F. Gastrostomy tubes in patients with advanced head and neck cancer. Laryngoscope 2005;115:44-7.
6. Lefebvre J. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 2005;16:vi7-12.
7. Thariat J, Yildirim G, Mason K, et al. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol 2007;12:99-110.
8. Bianco R, Shin I, Ritter C, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-22.
9. Wheeler D, Huang S, Kruser T, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944-56.
10. Sok J, Coppelli F, Thomas S, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-73.
11. Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008;98:923-30.
12. Janmaat M, Kruyt F, Rodriguez J, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
13. Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005;65:9953-61.
14. Datta S, Brunet A, Greenberg M. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
15. Molinolo A, Hewitt S, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007;13:4964-73.
16. Nathan C, Amirghahar N, Abreo F , et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2004;10:5820-7.
17. Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004;10:4029-37.
18. Sunavala-Dossabhoy G, Fowler M, Benedetti AD. Translation of the radioresistance kinase TLK1B is induced by γ-irradiation through activation of mTOR and phosphorylation of 4E-BP1. BMC Mol Biol 2004;5:1.
19. Reits E, Hodge J, Herberts C, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203:1259-71.
20. Chan S, Scheulen M, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22.
21. Hidalgo M, Buckner J, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks topatients with advanced cancer. Clin Cancer Res 2006;12:5755-63.
22. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47.
23. Sarkaria J, Schwingler P, Schild S, et al. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol 2007;2:751-7.
24. Albert J, Kim K, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006;5:1183-9.
25. Cao C, Subhawong T, Albert J, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006;66:10040-7.
26. Shinohara E, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005;24:5414-22.
27. Nathan C, Amirghahari N, Rong X, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007;67:2160-8.
28. Shalinsky D, Bischoff E, Gregory M, et al. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 1996;2:511-20.
29. Dudkin L, Dilling M, Cheshire P, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001;7:1758-64.
30. Mabuchi S, Altomare D, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-70.
31. Wu L, Birle D, Tannock I. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65:2825-31.
32. Zitzmann K, Toni ED, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007;85:54-60.
33. Dancey J, Chen H. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649-59.
34. Tan J, Geng L, Yazlovitskaya E, Hallahan D. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3β in irradiated vascular endothelium. Cancer Res 2006;66:2320-7.
35. Bufalo DD, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549-54.
36. Guba M, Breitenbuch Pv, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
37. Wan X, Shen N, Mendoza A, Khanna C, Helman L. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked tothe targeting of mTOR/Hif-1α/VEGF signaling. Neoplasia 2006;8:394-401.
38. Brieger J, Kattwinkel J, Berres M, Gosepath J, Mann W. Impact of vascular endothelial growth factor release on radiation resistance. Oncol Rep 2007;18:1597-601.
39. Sun S, Rosenberg L, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.
40. O'Reilly K, Rojo F, She Q, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.